# A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

> clinical trial · VERIFIED · 2026-07-08

Status: ACTIVE_NOT_RECRUITING · Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Condition: Non-Small Cell Lung Cancer

- Company: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Sector: Non-Small Cell Lung Cancer
- Primary source: https://clinicaltrials.gov/study/NCT06711900

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.